655 related articles for article (PubMed ID: 16582916)
21. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.
Modlich U; Schambach A; Brugman MH; Wicke DC; Knoess S; Li Z; Maetzig T; Rudolph C; Schlegelberger B; Baum C
Leukemia; 2008 Aug; 22(8):1519-28. PubMed ID: 18496560
[TBL] [Abstract][Full Text] [Related]
22. Medicine. Gene therapy--new challenges ahead.
Williams DA; Baum C
Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy for chronic granulomatous disease.
Kume A; Dinauer MC
J Lab Clin Med; 2000 Feb; 135(2):122-8. PubMed ID: 10695656
[TBL] [Abstract][Full Text] [Related]
24. Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B; Roeder I
Gene Ther; 2008 Jan; 15(2):143-53. PubMed ID: 17972922
[TBL] [Abstract][Full Text] [Related]
25. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
26. Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation.
Sadat MA; Dirscherl S; Sastry L; Dantzer J; Pech N; Griffin S; Hawkins T; Zhao Y; Barese CN; Cross S; Orazi A; An C; Goebel WS; Yoder MC; Li X; Grez M; Cornetta K; Mooney SD; Dinauer MC
Gene Ther; 2009 Dec; 16(12):1452-64. PubMed ID: 19657370
[TBL] [Abstract][Full Text] [Related]
27. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.
Calmels B; Ferguson C; Laukkanen MO; Adler R; Faulhaber M; Kim HJ; Sellers S; Hematti P; Schmidt M; von Kalle C; Akagi K; Donahue RE; Dunbar CE
Blood; 2005 Oct; 106(7):2530-3. PubMed ID: 15933056
[TBL] [Abstract][Full Text] [Related]
28. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
Kustikova O; Fehse B; Modlich U; Yang M; Düllmann J; Kamino K; von Neuhoff N; Schlegelberger B; Li Z; Baum C
Science; 2005 May; 308(5725):1171-4. PubMed ID: 15905401
[TBL] [Abstract][Full Text] [Related]
29. Granulocyte colony-stimulating factor prior to nonmyeloablative irradiation decreases murine host hematopoietic stem cell function and increases engraftment of donor marrow cells.
Barese C; Pech N; Dirscherl S; Meyers JL; Sinn AL; Yoder MC; Goebel WS; Dinauer MC
Stem Cells; 2007 Jun; 25(6):1578-85. PubMed ID: 17347493
[TBL] [Abstract][Full Text] [Related]
30. The expression of full length Gp91-phox protein is associated with reduced amphotropic retroviral production.
Bellantuono I; Lashford LS; Rafferty JA; Fairbairn LJ
Haematologica; 2000 May; 85(5):451-7. PubMed ID: 10800158
[TBL] [Abstract][Full Text] [Related]
31. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells.
Moreno-Carranza B; Gentsch M; Stein S; Schambach A; Santilli G; Rudolf E; Ryser MF; Haria S; Thrasher AJ; Baum C; Brenner S; Grez M
Gene Ther; 2009 Jan; 16(1):111-8. PubMed ID: 18784749
[TBL] [Abstract][Full Text] [Related]
32. Chronic granulomatous disease: towards gene therapy.
Thrasher A; Segal A; Casimir C
Immunodeficiency; 1993; 4(1-4):327-33. PubMed ID: 8167728
[TBL] [Abstract][Full Text] [Related]
33. Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease.
Rappa G; Anzanello F; Alexeyev M; Fodstad O; Lorico A
Eur J Haematol; 2007 May; 78(5):440-8. PubMed ID: 17331133
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy advances but struggles to interpret safety data in small animal models.
Williams DA
Mol Ther; 2006 Jun; 13(6):1027-8. PubMed ID: 16684622
[No Abstract] [Full Text] [Related]
35. [Prospects for gene therapy for chronic granulomatous disease with gp91-phox deficiency].
Nunoi H; Sugimoto Y; Kanegasaki S
Rinsho Ketsueki; 1998 Feb; 39(2):132. PubMed ID: 9545823
[No Abstract] [Full Text] [Related]
36. Skewing of X-chromosome inactivation in three generations of carriers with X-linked chronic granulomatous disease within one family.
Köker MY; Sanal O; de Boer M; Tezcan I; Metin A; Tan C; Ersoy F; Roos D
Eur J Clin Invest; 2006 Apr; 36(4):257-64. PubMed ID: 16620288
[TBL] [Abstract][Full Text] [Related]
37. Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3.
Khanna-Gupta A; Lopingco MC; Savinelli T; Zibello T; Berliner N; Perkins AS
Oncogene; 1996 Feb; 12(3):563-9. PubMed ID: 8637713
[TBL] [Abstract][Full Text] [Related]
38. Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD.
Schwickerath O; Brouns G; Thrasher A; Kinnon C; Roes J; Casimir C
J Gene Med; 2004 Jun; 6(6):603-15. PubMed ID: 15170731
[TBL] [Abstract][Full Text] [Related]
39. Advances in the treatment of Chronic Granulomatous Disease by gene therapy.
Ott MG; Seger R; Stein S; Siler U; Hoelzer D; Grez M
Curr Gene Ther; 2007 Jun; 7(3):155-61. PubMed ID: 17584034
[TBL] [Abstract][Full Text] [Related]
40. Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing.
Siler U; Paruzynski A; Holtgreve-Grez H; Kuzmenko E; Koehl U; Renner ED; Alhan C; de Loosdrecht AA; Schwäble J; Pfluger T; Tchinda J; Schmugge M; Jauch A; Naundorf S; Kühlcke K; Notheis G; Güngor T; Kalle CV; Schmidt M; Grez M; Seger R; Reichenbach J
Curr Gene Ther; 2015; 15(4):416-27. PubMed ID: 25981636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
